Comparison of Two Doses and Two Routes of Administration of Misoprostol after Pre-Treatment with Mifepristone for Early Pregnancy Termination

BACKGROUND: It is not known whether a 400 microg dose of misoprostol has a similar efficacy as an 800 microg dose when administered sublingually or vaginally 24 hours after 200 mg mifepristone. METHODS: It is proposed to undertake a placebo-controlled, randomized, non-inferiority trial (3% margin of equivalence) of the two misoprostol doses when administered sublingually or vaginally using factorial design. A total of 3008 pregnant women (< 63 days of gestational age) who request legal termination of pregnancy will be recruited for the trial at 16 clinics in ten countries providing abortion services. Eligible women willing to join the study will be allocated randomly to one of the four treatment groups within each centre. Women in all treatment groups will first receive 200 mg mifepristone, followed 24 hours later by either 400 microg or 800 microg misoprostol, administered either sublingually or vaginally. The dose and route of administration of misoprostol will be blinded to women, each woman receiving four tablets vaginally and four tablets sublingually, two or four of which are 200 microg tablets of misoprostol and the rest are placebo tablets.The four treatment regimens will be compared in terms of: (i) their efficacy to induce complete abortion; (ii) induction-to-abortion interval when possible; (iii) the frequency of side effects; and (iv) women's perceptions. The initial judgment of the outcome of treatment is made at the follow-up visit on day 15 of the study and the final assessment four weeks later. It is estimated that the clinical phase will require 12-14 months for data collection.To compare the two routes and two doses, relative risks (RR) of failure to achieve a complete abortion and failure to terminate pregnancy and the two-sided 95% CIs will be calculated by standard methods, as well as risk differences and two-sided 95% CIs. The latter will be used to test the non-inferiority hypotheses (at 2.5% level of significance) for achieving complete abortion. The factorial structure will be taken into account in the analysis after testing the interaction. TRIAL REGISTRATION: ISRCTN87811512.

Saved in:
Bibliographic Details
Main Authors: von Hertzen, H., Piaggio, G., Marions, L.
Format: Journal Article biblioteca
Language:EN
Published: 2008
Online Access:http://hdl.handle.net/10986/5140
Tags: Add Tag
No Tags, Be the first to tag this record!
id dig-okr-109865140
record_format koha
spelling dig-okr-1098651402021-04-23T14:02:21Z Comparison of Two Doses and Two Routes of Administration of Misoprostol after Pre-Treatment with Mifepristone for Early Pregnancy Termination von Hertzen, H. Piaggio, G. Marions, L. BACKGROUND: It is not known whether a 400 microg dose of misoprostol has a similar efficacy as an 800 microg dose when administered sublingually or vaginally 24 hours after 200 mg mifepristone. METHODS: It is proposed to undertake a placebo-controlled, randomized, non-inferiority trial (3% margin of equivalence) of the two misoprostol doses when administered sublingually or vaginally using factorial design. A total of 3008 pregnant women (< 63 days of gestational age) who request legal termination of pregnancy will be recruited for the trial at 16 clinics in ten countries providing abortion services. Eligible women willing to join the study will be allocated randomly to one of the four treatment groups within each centre. Women in all treatment groups will first receive 200 mg mifepristone, followed 24 hours later by either 400 microg or 800 microg misoprostol, administered either sublingually or vaginally. The dose and route of administration of misoprostol will be blinded to women, each woman receiving four tablets vaginally and four tablets sublingually, two or four of which are 200 microg tablets of misoprostol and the rest are placebo tablets.The four treatment regimens will be compared in terms of: (i) their efficacy to induce complete abortion; (ii) induction-to-abortion interval when possible; (iii) the frequency of side effects; and (iv) women's perceptions. The initial judgment of the outcome of treatment is made at the follow-up visit on day 15 of the study and the final assessment four weeks later. It is estimated that the clinical phase will require 12-14 months for data collection.To compare the two routes and two doses, relative risks (RR) of failure to achieve a complete abortion and failure to terminate pregnancy and the two-sided 95% CIs will be calculated by standard methods, as well as risk differences and two-sided 95% CIs. The latter will be used to test the non-inferiority hypotheses (at 2.5% level of significance) for achieving complete abortion. The factorial structure will be taken into account in the analysis after testing the interaction. TRIAL REGISTRATION: ISRCTN87811512. 2012-03-30T07:31:30Z 2012-03-30T07:31:30Z 2008 Journal Article Reprod Health 1742-4755 (Electronic) 1742-4755 (Linking) http://hdl.handle.net/10986/5140 EN http://creativecommons.org/licenses/by-nc-nd/3.0/igo World Bank Journal Article
institution Banco Mundial
collection DSpace
country Estados Unidos
countrycode US
component Bibliográfico
access En linea
databasecode dig-okr
tag biblioteca
region America del Norte
libraryname Biblioteca del Banco Mundial
language EN
description BACKGROUND: It is not known whether a 400 microg dose of misoprostol has a similar efficacy as an 800 microg dose when administered sublingually or vaginally 24 hours after 200 mg mifepristone. METHODS: It is proposed to undertake a placebo-controlled, randomized, non-inferiority trial (3% margin of equivalence) of the two misoprostol doses when administered sublingually or vaginally using factorial design. A total of 3008 pregnant women (< 63 days of gestational age) who request legal termination of pregnancy will be recruited for the trial at 16 clinics in ten countries providing abortion services. Eligible women willing to join the study will be allocated randomly to one of the four treatment groups within each centre. Women in all treatment groups will first receive 200 mg mifepristone, followed 24 hours later by either 400 microg or 800 microg misoprostol, administered either sublingually or vaginally. The dose and route of administration of misoprostol will be blinded to women, each woman receiving four tablets vaginally and four tablets sublingually, two or four of which are 200 microg tablets of misoprostol and the rest are placebo tablets.The four treatment regimens will be compared in terms of: (i) their efficacy to induce complete abortion; (ii) induction-to-abortion interval when possible; (iii) the frequency of side effects; and (iv) women's perceptions. The initial judgment of the outcome of treatment is made at the follow-up visit on day 15 of the study and the final assessment four weeks later. It is estimated that the clinical phase will require 12-14 months for data collection.To compare the two routes and two doses, relative risks (RR) of failure to achieve a complete abortion and failure to terminate pregnancy and the two-sided 95% CIs will be calculated by standard methods, as well as risk differences and two-sided 95% CIs. The latter will be used to test the non-inferiority hypotheses (at 2.5% level of significance) for achieving complete abortion. The factorial structure will be taken into account in the analysis after testing the interaction. TRIAL REGISTRATION: ISRCTN87811512.
format Journal Article
author von Hertzen, H.
Piaggio, G.
Marions, L.
spellingShingle von Hertzen, H.
Piaggio, G.
Marions, L.
Comparison of Two Doses and Two Routes of Administration of Misoprostol after Pre-Treatment with Mifepristone for Early Pregnancy Termination
author_facet von Hertzen, H.
Piaggio, G.
Marions, L.
author_sort von Hertzen, H.
title Comparison of Two Doses and Two Routes of Administration of Misoprostol after Pre-Treatment with Mifepristone for Early Pregnancy Termination
title_short Comparison of Two Doses and Two Routes of Administration of Misoprostol after Pre-Treatment with Mifepristone for Early Pregnancy Termination
title_full Comparison of Two Doses and Two Routes of Administration of Misoprostol after Pre-Treatment with Mifepristone for Early Pregnancy Termination
title_fullStr Comparison of Two Doses and Two Routes of Administration of Misoprostol after Pre-Treatment with Mifepristone for Early Pregnancy Termination
title_full_unstemmed Comparison of Two Doses and Two Routes of Administration of Misoprostol after Pre-Treatment with Mifepristone for Early Pregnancy Termination
title_sort comparison of two doses and two routes of administration of misoprostol after pre-treatment with mifepristone for early pregnancy termination
publishDate 2008
url http://hdl.handle.net/10986/5140
work_keys_str_mv AT vonhertzenh comparisonoftwodosesandtworoutesofadministrationofmisoprostolafterpretreatmentwithmifepristoneforearlypregnancytermination
AT piaggiog comparisonoftwodosesandtworoutesofadministrationofmisoprostolafterpretreatmentwithmifepristoneforearlypregnancytermination
AT marionsl comparisonoftwodosesandtworoutesofadministrationofmisoprostolafterpretreatmentwithmifepristoneforearlypregnancytermination
_version_ 1756571589077368832